Company Description
Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer.
The company’s pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory.
The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University.
The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015.
Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 40 |
| CEO | William Quinn |
Contact Details
Address: 900 Chesapeake Drive Redwood City, California 94063 United States | |
| Phone | 650 665 9295 |
| Website | boltbio.com |
Stock Details
| Ticker Symbol | BOLT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 1641281 |
| CUSIP Number | 097702203 |
| ISIN Number | US0977022039 |
| Employer ID | 47-2804636 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William P. Quinn | Chief Executive Officer, Chief Financial Officer, President, Secretary and Director |
| Grant Yonehiro C.F.A., M.B.A. | Chief Operating Officer and Chief Business Officer |
| Sarah Nemec | Senior Vice President of Finance and Principal Accounting Officer |
| Dr. Michael N. Alonso Ph.D. | Senior Vice President of Research |
| Justin Kenkel | Senior Principal Scientist |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 12, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 12, 2026 | 10-K | Annual Report |
| Mar 12, 2026 | 8-K | Current Report |
| Feb 26, 2026 | SCHEDULE 13D/A | Filing |
| Feb 17, 2026 | SCHEDULE 13D/A | Filing |
| Feb 13, 2026 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 14, 2025 | SCHEDULE 13G/A | Filing |
| Nov 12, 2025 | 10-Q | Quarterly Report |
| Nov 12, 2025 | 8-K | Current Report |